Faillie, Jean-Luc
Inserm · Université de Montpellier · Centre Hospitalier Universitaire de Montpellier · Institut Desbrest d'Epidémiologie et de Santé Publique
7 papers on CoChatORCID 0000-0003-0100-4073
Most cited papers
- Verified
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies
Pharmacovigilance and Adverse Drug ReactionsStatistical Methods in Clinical Trials
Cited by 336
- Verified
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care
Diabetes Treatment and ManagementThyroid Cancer Diagnosis and Treatment
Cited by 320
- Verified
Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus.
Faillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016) · JAMA Internal Medicine
Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders
Cited by 134
- Verified
Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French pharmacovigilance database
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica
Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug Reactions
Cited by 70
- Verified
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 67
- Verified
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study
Gudin, B., Ladhari, C., Robin, P., Laroche, M.-L., Babai, S., Hillaire-Buys, D., & Faillie, J.-L. (2020) · Therapies
Pharmacovigilance and Adverse Drug ReactionsDiabetes Treatment and Management
Cited by 37
- Verified
Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390
Bezin, J., Mathieu, C., Faillie, J.-L., & Pariente, A. (2023) · Diabetes Care
Diabetes Treatment and ManagementThyroid Disorders and Treatments
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free